Women represent a significant and growing segment of peptide users, yet most peptide research has historically been conducted primarily in male subjects or mixed populations without sex-stratified analysis. This guide highlights peptides with evidence, safety profiles, or applications particularly relevant to women, including weight management, skin health, healing, and sexual function.
We prioritize peptides with either female-specific clinical data, FDA approval with established use in women, or mechanisms that address health concerns disproportionately affecting women. Safety during pregnancy, breastfeeding, and in the context of hormonal fluctuations receives specific attention where data is available.
Important: This guide is for educational purposes only. Women who are pregnant, breastfeeding, or planning pregnancy should avoid all research peptides unless specifically prescribed by their healthcare provider. Hormonal peptides may interact with oral contraceptives and hormone replacement therapy. All peptide use should be discussed with a qualified healthcare provider.
Semaglutide
Best for: Evidence-backed weight management with the most female-inclusive clinical data
Semaglutide is FDA-approved for weight management and type 2 diabetes, with extensive clinical trial data that includes female participants. Women made up approximately 70% of participants in the STEP trials. It is the most evidence-backed weight loss peptide available to women, with well-characterized safety data including fertility considerations (the label recommends discontinuing 2 months before planned pregnancy due to long half-life).
Tirzepatide
Best for: Maximum weight loss with potential relevance to insulin resistance and PCOS
Tirzepatide demonstrated the highest weight loss of any single-agent peptide in Phase 3 trials, with similar efficacy in female and male subgroups. Its dual GLP-1/GIP mechanism may offer advantages for women with insulin resistance or PCOS-related weight gain. Like semaglutide, it requires pregnancy precautions and is not approved for use during pregnancy or breastfeeding.
GHK-Cu
Best for: Skin rejuvenation and anti-aging with OTC availability and excellent safety profile
GHK-Cu is the most evidence-backed cosmetic peptide, with published human studies showing improvements in skin collagen density, elasticity, and fine lines. It is available over-the-counter in serums and creams without prescription. It has an excellent safety profile for topical use, no hormonal effects, and no pregnancy-specific concerns for topical application — though systemic use (injection) during pregnancy has not been studied.
BPC-157
Best for: Broad-spectrum tissue repair and post-surgical recovery support
BPC-157 is the most widely studied healing peptide with over 100 preclinical studies. Its relevance to women includes recovery from surgical procedures, pelvic floor injuries, and general musculoskeletal healing. No sex-specific adverse effects have been identified in preclinical research. However, it lacks human clinical trials and is not recommended during pregnancy or breastfeeding due to insufficient safety data.
Collagen Peptides
Best for: OTC supplement for skin, joint, nail, and bone health (postmenopausal relevance)
Collagen peptides have the most extensive human clinical trial data of any peptide supplement, with multiple RCTs demonstrating improvements in skin hydration, elasticity, and wrinkle depth. They also show benefits for joint health, nail strength, and bone density — concerns that disproportionately affect women, particularly postmenopausal women experiencing estrogen-related collagen decline. They are available as OTC supplements with an excellent safety profile.
PT-141
Best for: FDA-approved treatment for hypoactive sexual desire disorder in premenopausal women
PT-141 (bremelanotide, brand name Vyleesi) is the only peptide on this list that is FDA-approved specifically for a female indication — hypoactive sexual desire disorder (HSDD) in premenopausal women. It works through the melanocortin-4 receptor to enhance sexual desire. Clinical trials were conducted exclusively in women. Common side effects include nausea, flushing, and injection site reactions.
Frequently asked questions
Safety depends on the specific peptide. FDA-approved peptides like semaglutide, tirzepatide, and PT-141 (bremelanotide) have undergone rigorous clinical trials that included women. OTC peptides like collagen peptides and GHK-Cu topical products have excellent safety profiles. Research peptides without human clinical data carry more uncertainty. All peptide use should be discussed with a healthcare provider, especially regarding hormonal interactions.
Most peptides lack pregnancy safety data and should be avoided during pregnancy and breastfeeding. Semaglutide and tirzepatide labels specifically recommend discontinuation before planned pregnancy (semaglutide: 2 months prior due to long half-life). Topical GHK-Cu has not been studied in pregnancy for systemic effects. Oral collagen peptides are generally considered safe during pregnancy but consult your healthcare provider. When in doubt, discontinue.
PT-141 (bremelanotide, brand name Vyleesi) is a melanocortin-4 receptor agonist FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. While the FDA approval is female-specific, PT-141 has also been studied for erectile dysfunction in men. The mechanism is central (brain-based) rather than peripheral, distinguishing it from agents like sildenafil.
GLP-1 receptor agonists (semaglutide, tirzepatide) can slow gastric emptying, which may reduce absorption of oral medications including oral contraceptives. The prescribing information for these peptides recommends using a non-oral backup contraceptive method or monitoring for breakthrough bleeding. Non-GLP-1 peptides (BPC-157, GHK-Cu, collagen peptides) are not known to interact with oral contraceptives.
Collagen peptides address the accelerated collagen decline that occurs after menopause (women lose approximately 30% of skin collagen in the first 5 years after menopause). GHK-Cu supports skin elasticity and wound healing. BPC-157 may support joint and tendon health. None of these replace hormone replacement therapy for menopausal symptoms — they address specific concerns like skin, joint, and bone health.